Akebia Therapeutics, Inc. (AX9.F)
| Previous close | 0.9900 |
| Open | 0.9900 |
| Bid | 0.9720 x 30000 |
| Ask | 1.0170 x 30000 |
| Day's range | 0.9900 - 0.9900 |
| 52-week range | 0.7410 - 2.8500 |
| Volume | |
| Avg. volume | 505 |
| Market cap | 207.5M |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2000 |
| Earnings date | 23 Aug 2024 - 27 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.54 |
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase an aggregate of 76,000 shares of Akebia's common stock on May 31, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
- PR Newswire
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 9:00 a.m. ET.
- PR Newswire
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on Monday, May 20th, 2024 at 3:00 p.m. ET.
